Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
about
Adherence and drug resistance: predictions for therapy outcomeApricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutationsIn vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analoguesAntiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv miceSelection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidineA novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineHuman immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years"Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practicePatterns of transmitted HIV drug resistance in Europe vary by risk groupAzvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitroEmergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzeeEvolutionary dynamics of HIV-induced subversion of the immune response.Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patientsBritish HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998).A spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidineHuman immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapyIncreased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitroGenotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapyEffect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathyHuman immunodeficiency virus drug resistance testing: state of the art in genotypic and phenotypic testing of antiretrovirals.Population genetic analysis of the protease locus of human immunodeficiency virus type 1 quasispecies undergoing drug selection, using a denaturing gradient-heteroduplex tracking assay.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.Incidence and impact of resistance against approved antiretroviral drugs.A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC)Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudineCharacterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.Antiretroviral therapy for human immunodeficiency virus infection in 1997.Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.Differential susceptibility of retroviruses to nucleoside analogues.Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine.Rapid emergence of protease inhibitor resistance in hepatitis C virus.The effects of internal primer-template mismatches on RT-PCR: HIV-1 model studiesThe HBV drug entecavir - effects on HIV-1 replication and resistanceHigher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.
P2860
Q27477742-ABE2926A-6640-441A-A4A8-49EC28BEE205Q28235418-24F05A8E-F5E1-4C5D-9212-42F518512526Q28343615-80D4ED8B-538B-4073-A3D6-21388CFAF64FQ28343930-F57E90EC-1A42-4F2E-B503-B300338EC38DQ28344137-1472B8DD-87B5-4055-913D-CABA3D62A0AEQ28379499-E2511847-957C-4E2C-8C00-91E0659E77B4Q28379519-E29FAA7B-9591-4A11-A31C-A5155553EB7CQ28477270-E04C80B3-C693-4FC1-961D-1AC75C0BBE7FQ28537726-CC9B189E-D947-4E08-A752-069B9D9F779CQ28542490-CCC9D358-9BF9-477C-9D8C-8EBCA1BEDF85Q29619254-6B292E28-EE38-4F50-B70D-C674609AEDAFQ33442370-335AD195-5A38-43D8-BEED-8271521C6011Q33683341-7F7832C4-C58C-434D-A067-E1C98C1FA0A1Q33699597-FA403CD0-04C8-4618-A27C-27D68724D582Q33711667-7846D9D9-2B11-47FB-A77D-34A050C0F483Q33728690-672E9BAA-547D-4C01-8A44-8DE907325AA0Q33737755-857E8C5F-0ADF-4150-AD82-D415AE991FF8Q33743954-ABDBC286-0341-4BBE-87D5-CBC216FD069AQ33782477-B7D315BC-0EDB-4ADE-990F-FD4780A0E97FQ33782492-70330A03-467D-4745-9F19-F76F05AFAF40Q33782815-A626AF66-D5BD-44A5-BC6D-2846AF7665E7Q33784635-EB92B4BC-C7DB-4538-AE9A-526959E3D4DFQ33825371-393B402C-F0C7-4AF0-A8B7-ADB7148340E0Q33839756-6806DBE9-F8B5-4067-B06D-56B4922B7802Q33843999-BB3D741D-CC14-41A3-A9F6-287D5C5BCA5DQ33906239-30C6A7A1-F5C2-47E3-B769-18E1C514AE17Q33961507-7E0B4ABF-ECD8-438D-AB49-041945A66B79Q33966248-F98F02B0-CD60-4427-9482-C1112F0B02F3Q33976011-FA5DE955-6521-4C15-BA2B-41CE394C981AQ33977402-B4531F25-5CAF-48AD-9BB3-653F1CD53073Q33981009-2BE6A086-58A0-4C1A-8564-0EA7EB47DE88Q34185841-CDCC5D87-0AA4-4EF2-91B9-F4E9F8D3185EQ34339657-77C548E3-51F2-42EB-A619-9927EC62284EQ34349394-0E56BF71-6520-4EA9-97B8-3D1D778EB38CQ34465037-9A0C86B7-1201-43A5-877A-E701E82088A7Q34551913-B52D5939-9B5A-4512-AC6E-16E0E5F0CE06Q34625250-2078118D-7AD2-4528-9385-4850316845E5Q34639926-8D2CD39D-BC67-4A02-A6A4-076BDF7BB64CQ34644794-912B89D6-E759-4CBF-8A8D-B4C7F8649C0BQ34668716-CCA35962-E1CC-401B-B8DA-B83B1BB9E75A
P2860
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Rapid changes in human immunod ...... treated with lamivudine (3TC).
@en
Rapid changes in human immunod ...... ersons treated with lamivudine
@nl
type
label
Rapid changes in human immunod ...... treated with lamivudine (3TC).
@en
Rapid changes in human immunod ...... ersons treated with lamivudine
@nl
prefLabel
Rapid changes in human immunod ...... treated with lamivudine (3TC).
@en
Rapid changes in human immunod ...... ersons treated with lamivudine
@nl
P2093
P356
P1476
Rapid changes in human immunod ...... treated with lamivudine (3TC).
@en
P2093
Christopherson C
Schipper P
Schuurman R
van Leeuwen R
P304
P356
10.1093/INFDIS/171.6.1411
P407
P577
1995-06-01T00:00:00Z